ArticleJournal of imaging informatics in medicine2026
3D deep learning model to predict the recurrence of stage IA invasive lung adenocarcinoma after sub-lobar resection: a multicenter retrospective cohort study.
Article in Journal of imaging informatics in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The purpose of this study was to investigate the efficacy of a three-dimensional (3D) deep learning (DL) model in predicting recurrence risk of stage IA invasive lung adenocarcinoma (ILADC) after sub-lobar resection (SLR). A total of 287 stage IA ILADC patients were assigned to training and internal validation sets (4:1), with an external test cohort of 112 patients from two institutions. Three clinical models, five 3D DL models and a combined clinic-radiological-DL model were developed. Model performance was compared to identify the best-performing one. Patients were stratified into high/low-risk groups using the optimal predictive probability threshold from the best model. Survival analysis was performed to compare prognosis between groups. Furthermore, the pathological-molecular characteristics of tumors were compared between high/low-risk groups. Among clinical models, SVM achieved the highest AUCs (training: 0.819, internal validation: 0.785, and external testing: 0.758). The 3D VGG-16 DL model outperformed others with AUCs of 0.921, 0.856, and 0.830, respectively. The combined model yielded AUCs of 0.932, 0.882, and 0.854, respectively. Both 3D VGG-16 and the combined model showed significantly higher sensitivity than the clinical model (all p < 0.05). High-risk patients classified by 3D VGG-16 model had shorter recurrence-free survival/overall survival (all p < 0.05) and higher prevalence of micropapillary/solid-predominant growth pattern, STAS, and mutations or fusions in KRAS and ALK (all p < 0.05). 3D VGG-16 effectively predicts post-SLR recurrence risk for stage IA ILADC, serving as a potential tool to guide surgical treatment decisions.
Indexed as
Identifiers
41917242What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.